Effect of intraperitoneal administration of heparin on advanced glycation end-products in CAPD

Peritoneal Dialysis International

Volumn 19, Issue 4, 1999, Pages 361-365

  Mizuiri, Sonoo ^a   Miyata, Satoshi ^b   Sakai, Ken ^a   Kobayashi, Miyuki ^a   Miyagi, Moriatsu ^a   Nakanishi, Tsutomu ^a   Liu, Bing Fen ^b   Kojima, Hiroshi ^b   Hasegawa, Akira ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; AGEs; Heparin; Pyrraline

Indexed keywords

ADVANCED GLYCATION END PRODUCT; COLLAGEN; CREATININE; HEPARIN; PYRRALINE; UNCLASSIFIED DRUG; UREA;

ADULT; ARTICLE; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIALYSATE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; HUMAN; HUMAN TISSUE; KINETICS; MEMBRANE DAMAGE; PERITONEUM; PLASMA; PRIORITY JOURNAL;

EID: 0033437135     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901900413     Document Type: Article

References (20)

1. Ponce SP, Barata JD, Santos JR. Interference of heparin with peritoneal solute transport. Nephron 1985; 39:47-9.
2. Miranda B, Selgas R, Celadilla O, Munoz J, Sicilia LS. Peritoneal resting and heparinization as an effective treatment for ultrafiltration failure in patients on CAPD. Contrib Nephrol 1991; 89:199-204.
3. Gambaro G, Fracasso A, Re G, Fries W, Baggio B, Bazzato G. Glycosaminoglycans (GAGS) improve peritoneal transport and fibrosis in rats with peritoneal sclerosis induced by diethylhexylphthalate (DEHP) (Abstract). J Am Soc Nephrol 1994; 5:448.
4. Bazzato G, Fracasso A, Gambaro G, Baggio B. Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet 1995; 346:740-1.
5. Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Garbisa S, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994; 46:797-806.
6. Yokoyama H, Myrup B, Oturai P, Deckert T. Heparin, a possible therapy for diabetic complications: the effect on mesangial and inyomedial cells in vivo and in vitro, especially in relation to extracellular matrix. J Diabetes Complications 1995; 9:97-103.
7. Monnier VM, Cerami A. Non-enzymatic browning in vivo: possible process for aging of long-lived proteins. Science 1981; 211:491-3.
8. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM. Aging of proteins: immunological detection of glucose-derived pyrrole formed during Maillard reaction in vivo. J Biol Chem 1989; 264:3758-64.
9. Miyata S, Monnier VM. Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. J Clin Invest 1992; 89:1102-12.
10. Miyata S, Liu B-F, Shoda H, Ohara T, Yamada H, Suzuki K, et al. Accumulation of pyrraline-modified albumin in phagocytes due to reduced degradation by lysosomal enzymes. J Biol Chem 1997; 272:4037-42.
11. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
12. Friedlander MA, Wu YC, Elgawish A, Monnier VM. Early and advanced glycosylation endproducts: kinetics of formation and clearance in peritoneal dialysis. J Clin Invest 1996; 97:728-35.
13. Brunkhorst R, Kruse M, Ehlerding G, Mahiout A. Advanced glycosylated endproducts (AGEs) in nondiabetic patients undergoing dialysis. Clin Nephrol 1996; 46:265-6.
14. Vlassara H, Brownlee M, Cerami A. Novel macrophage receptor for glucose-modified protein is distinct from previously described scavenger receptors. J Exp Med 1986; 164:1301-9.
15. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest 1995; 96:1395-403.
16. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997; 386:292-6.
17. Vlassara H, Brownlee M, Manogue KR, Dinarello C, Pasagian A. Cachectin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue remodeling. Science 1988; 240:1546-8.
18. Watanabe N, Kamei S, Ohkubo A, Yamanaka M, Ohsawa S, Makino K, et al. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 1986; 32:1551-4.
19. Odani H, Shinzato T, Matsumoto Y, Takai I, Nakai S, Miwa M, et al. First evidence for accumulation of protein bound and protein free pyrraline in human uremic plasma by mass spectrometry. Biochem Biophys Res Commun 1996; 224:237-41.
20. Sell DR, Monnier VM. End stage renal failure disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 1990; 85:380-4.